Senseonics(US:SENS)2020-11-11 15:13Product & Technology - Eversense CGM System is the first and only long-term continuous glucose monitoring system[7] - 92% of patients reported no pain or discomfort when using the sensor[3] - The company anticipates approval for a new Eversense 180-day sensor[12] - The company is developing a 365-day sensor with optional FGM point-in-time reading, planned for 2023[48] - The company is developing the Freedom System with an integrated battery and standalone FGM, planned for 2024[50] Commercialization & Partnership - Senseonics has a strategic partnership with Ascensia for global commercialization[14] - Ascensia has approximately $1 billion in global sales[14] - The company is focusing on growth and expansion with Ascensia's commercial organization[16] Financial Projections & Market - Estimated worldwide net revenue is projected to be in the range of $12 million to $15 million in 2021, increasing to $150 million to $200 million in 2025[19] - 32% of Eversense users are new to CGM, indicating market expansion[22] - Eversense has commercial and Medicare coverage for approximately 200 million covered lives since mid-2018[30]